Can your lung bacteria predict antibiotic failure?

NCT ID NCT06916481

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines how the community of bacteria in the lungs (the microbiome) affects how well pneumonia patients respond to antibiotics. Researchers will follow 300 adults with pneumonia, taking samples from the mouth, rectum, and lungs over 90 days. The goal is to see if the initial bacteria profile can predict treatment failure or the rise of antibiotic resistance, potentially leading to more personalized antibiotic choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which pneumonia patients will respond to antibiotics, reducing treatment failures and antibiotic resistance.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results may not apply to all pneumonia patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMUNITY ACQUIRED OR ACQUIRING HOSPITAL ACQUIRED PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Nantes

    ACTIVE_NOT_RECRUITING

    Nantes, France

  • CHU Nantes - Saint Herblain

    NOT_YET_RECRUITING

    Nantes, France

  • CHU Nantes - Saint Herblain

    NOT_YET_RECRUITING

    Nantes, France

  • Hospital Beaujon

    ACTIVE_NOT_RECRUITING

    Clichy, France

  • Hospital Bichat

    RECRUITING

    Paris, 75 018, France

  • Hospital Bichat

    ACTIVE_NOT_RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.